Lactobacillus reuteri

Drug Profile

Lactobacillus reuteri

Alternative Names: Apylori Probiotic Capsules; BioGaia ProTectis; IBP 9414; Lactobacillus reuteri ATCC 55730; Lactobacillus reuteri DSM 17938; Lactobacillus reuteri Protectis; NEC therapy - BioGaia

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BioGaia
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute enterocolitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastrointestinal disorders
  • Phase II Acute enterocolitis; Type 2 diabetes mellitus
  • Clinical Phase Unknown Colic; Constipation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-enterocolitis(Prevention) in Sweden (PO)
  • 01 May 2016 Phase-II clinical trials in Acute enterocolitis (In infants, Prevention) in USA (PO) (NCT02472769)
  • 22 Jun 2015 Infant Bacterial Therapeutics plans a phase II trial in Acute enterocolitis (In infants) in USA (NCT02472769)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top